NO20071299L - Vedvarende frigivelse farmasoytisk sammensetning av tolterodine - Google Patents

Vedvarende frigivelse farmasoytisk sammensetning av tolterodine

Info

Publication number
NO20071299L
NO20071299L NO20071299A NO20071299A NO20071299L NO 20071299 L NO20071299 L NO 20071299L NO 20071299 A NO20071299 A NO 20071299A NO 20071299 A NO20071299 A NO 20071299A NO 20071299 L NO20071299 L NO 20071299L
Authority
NO
Norway
Prior art keywords
pharmaceutical composition
tolterodine
sustained release
release pharmaceutical
composition
Prior art date
Application number
NO20071299A
Other languages
English (en)
Norwegian (no)
Inventor
Tadeja Rajer
Robert Pisek
Andrejka Kramer
Original Assignee
Krka Dd Novo Mesto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34926332&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20071299(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Krka Dd Novo Mesto filed Critical Krka Dd Novo Mesto
Publication of NO20071299L publication Critical patent/NO20071299L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20071299A 2004-08-27 2007-03-09 Vedvarende frigivelse farmasoytisk sammensetning av tolterodine NO20071299L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04020431A EP1629834A1 (de) 2004-08-27 2004-08-27 Pharmazeutische Zusammensetzung von Tolterodin mit verzögerter Freisetzung
PCT/EP2005/009102 WO2006021425A1 (en) 2004-08-27 2005-08-23 Sustained release pharmaceutical composition of tolterodine

Publications (1)

Publication Number Publication Date
NO20071299L true NO20071299L (no) 2007-05-29

Family

ID=34926332

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20071299A NO20071299L (no) 2004-08-27 2007-03-09 Vedvarende frigivelse farmasoytisk sammensetning av tolterodine

Country Status (7)

Country Link
EP (3) EP1629834A1 (de)
AT (1) ATE505187T1 (de)
DE (1) DE602005027469D1 (de)
EA (1) EA200700484A1 (de)
NO (1) NO20071299L (de)
UA (1) UA87515C2 (de)
WO (1) WO2006021425A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009530397A (ja) * 2006-03-21 2009-08-27 テバ ファーマシューティカル インダストリーズ リミティド トルテロジンの調節された開放性製剤
EP1839649A1 (de) 2006-03-31 2007-10-03 LEK Pharmaceuticals D.D. Beschichtete Formulierung von Tolterodine
KR100851033B1 (ko) * 2007-02-12 2008-08-12 명문제약주식회사 엘-주석산 톨터로딘 함유 서방성 제제의 제조방법
WO2009019599A2 (en) * 2007-08-08 2009-02-12 Themis Laboratories Private Limited Extended release compositions comprising tolterodine
WO2011061616A2 (en) 2009-11-23 2011-05-26 Micro Labs Limited Extended release compositions containing tolterodine and process for preparing the same
WO2011095388A1 (en) 2010-02-04 2011-08-11 Synthon Bv Tolterodine bead
GB2479213B (en) 2010-04-01 2013-07-10 Theravida Inc Pharmaceutical formulations for the treatment of overactive bladder
EP2706997B1 (de) 2011-05-10 2019-03-27 TheraVida, Inc. Kombinationen aus solifenacin und pilocarpin zur behandlung von hyperaktiver blase
CN103211784B (zh) * 2012-01-18 2017-07-11 北京天衡药物研究院有限公司 酒石酸托特罗定膜控缓释微丸胶囊
TW201422254A (zh) 2012-11-21 2014-06-16 Ferring Bv 用於速釋及延釋的組成物
CN108697688A (zh) 2016-01-20 2018-10-23 塞拉维达公司 用于治疗多汗症的方法和组合物

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE2061C1 (de) † 1890-01-25
SE8800207D0 (sv) 1988-01-22 1988-01-22 Kabivitrum Ab Nya aminer, deras anvendning och framstellning
SE9203318D0 (sv) 1992-11-06 1992-11-06 Kabi Pharmacia Ab Novel 3,3-diphenylpropylamines, their use and preparation
US6274171B1 (en) † 1996-03-25 2001-08-14 American Home Products Corporation Extended release formulation of venlafaxine hydrochloride
AU728395B2 (en) 1996-07-19 2001-01-11 Gunnar Aberg S(-)-tolterodine in the treatment of urinary and gastrointestinal disorders
KR20000057548A (ko) 1996-12-13 2000-09-25 알프레드 엘. 미첼슨 광학적 전송물질 및 결합재
EA002720B1 (ru) * 1998-08-27 2002-08-29 Фармациа Энд Апджон Аб Терапевтическая композиция для введения толтеродина с контролируемым высвобождением и способ лечения мочевого пузыря с её использованием
SE9803871D0 (sv) 1998-11-11 1998-11-11 Pharmacia & Upjohn Ab Therapeutic method and formulation
DE19901692C2 (de) † 1999-01-18 2002-06-20 Gruenenthal Gmbh Verfahren zur Herstellung von Pellets mit einem Gehalt von bis zu 90 Gew.% eines pharmazeutischen Wirkstoffes
CZ304671B6 (cs) * 1999-11-11 2014-08-27 Pharmacia Ab Farmaceutický prostředek obsahující tolterodin a jeho použití
SE9904850D0 (sv) 1999-12-30 1999-12-30 Pharmacia & Upjohn Ab Novel process and intermediates
IN191835B (de) 2001-08-03 2004-01-10 Ranbaxy Lab Ltd
US20030185882A1 (en) * 2001-11-06 2003-10-02 Vergez Juan A. Pharmaceutical compositions containing oxybutynin
US20030152624A1 (en) * 2001-12-20 2003-08-14 Aldrich Dale S. Controlled release dosage form having improved drug release properties
KR100540035B1 (ko) † 2002-02-01 2005-12-29 주식회사 태평양 다단계 경구 약물 방출 제어 시스템
US7005449B2 (en) 2002-04-23 2006-02-28 Pharmacia & Upjohn Company Tolterodine salts
CN1150160C (zh) 2002-04-29 2004-05-19 上海医药工业研究院 L－酒石酸托特罗定的合成方法
EP1635795A1 (de) 2003-05-30 2006-03-22 Ranbaxy Laboratories, Ltd. Pharmazeutische zusammensetzung mit kontrollierter freigabe von tolterodin sowie deren herstellung

Also Published As

Publication number Publication date
ATE505187T1 (de) 2011-04-15
EP1781275A1 (de) 2007-05-09
EP1629834A1 (de) 2006-03-01
EP1781275B2 (de) 2014-04-16
DE602005027469D1 (de) 2011-05-26
EA200700484A1 (ru) 2007-10-26
EP1781275B1 (de) 2011-04-13
WO2006021425A1 (en) 2006-03-02
EP1964553A1 (de) 2008-09-03
UA87515C2 (ru) 2009-07-27

Similar Documents

Publication Publication Date Title
NO20071299L (no) Vedvarende frigivelse farmasoytisk sammensetning av tolterodine
LTC1781298I2 (lt) Farmacinės kompozicijos, turinčios benzoksazino, skirtos respiracinių ligų gydymui
NO20074086L (no) Fremgangsmate for fremstilling av lansoprazol
NO20064041L (no) Substituerte pyrazolin sammensetninger, deres fremstilling og anvendelse som medikamenter
UY29112A1 (es) Derivados de pirazol condensado, su preparacion y su aplicacion terapeutica
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
DK1881967T3 (da) Substituerede benzo (D) isoaxol-3-yl-amin-forbindelser som analgetika
EA200870193A1 (ru) Цитотоксические агенты, включающие новые производные томаймицина, и их терапевтическое применение
NO345046B1 (no) Oral doseringsform
EA200700637A1 (ru) Соли донепезила, подходящие для получения фармацевтических композиций
CY1113024T1 (el) Σπειροκυκλικα παραγωγα κυκλοεξανιου για τη θεραπεια της εξαρτησης ουσιων
ATE484494T1 (de) Substituierte indolderivate für eine pharmazeutische zusammensetzung zur behandlung von atemwegserkrankungen
ATE453642T1 (de) Substituierte phenylaminopyrimidine
CY1111470T1 (el) Νεες φαρμακευτικες συνθεσεις που περιεχουν φλιβανσερινη πολυμορφη α
NO20065880L (no) 3-Amino-l-arylpropylindoler som monoamin-gjenopptagelsesinhibitor
EA201170753A1 (ru) Налмефена гидрохлорид дигидрат
NO20080967L (no) Benzimidazoler nyttige som inhibitorer av proteinkinaser
CY2018006I1 (el) Θεραπευτικο σχημα κλαδριβινης για την θεραπευτικη αντιμετωπιση της σκληρυνσης κατα πλακας
TW200612922A (en) Inhibitors of hsp90
WO2007025146A3 (en) Balsalazide formulations and manufacture and use thereof
NO20075920L (no) Assosiasjon mellom ferroquin og et artemisininderivat for behandling av malaria
CY1108916T1 (el) Υποκαθιστουμενες πυρρολες, οι ενωσεις που τις περιεχουν, διαδικασια παρασκευης και χρηση τους
CR7271A (es) Formulaciones farmaceuticas novedosas a base de melatonina y compuestos similares para su uso en transtornos del sueno
ATE541573T1 (de) Pharmazeutische zusammensetzung enthaltend lapatinib
WO2005082884A3 (en) 2-pyridin-2yl-pyrimidine derivatives useful in the treatment of gastro-esophagea l reflux disease

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application